Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Decrease in Short Interest

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a significant decrease in short interest in the month of December. As of December 15th, there was short interest totaling 3,088,368 shares, a decrease of 53.7% from the November 30th total of 6,675,820 shares. Based on an average trading volume of 737,184 shares, the short-interest ratio is presently 4.2 days. Approximately 6.4% of the shares of the stock are short sold. Approximately 6.4% of the shares of the stock are short sold. Based on an average trading volume of 737,184 shares, the short-interest ratio is presently 4.2 days.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Xilio Therapeutics in a report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Xilio Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $2.00.

Xilio Therapeutics Stock Performance

Shares of XLO stock opened at $0.66 on Friday. Xilio Therapeutics has a 52 week low of $0.62 and a 52 week high of $1.70. The stock has a market capitalization of $34.75 million, a PE ratio of -1.02 and a beta of -0.07. The stock’s fifty day moving average is $0.74 and its 200-day moving average is $0.73.

Xilio Therapeutics (NASDAQ:XLO) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.03). Xilio Therapeutics had a negative net margin of 183.90% and a negative return on equity of 679.66%. The business had revenue of $19.07 million for the quarter, compared to the consensus estimate of $18.64 million. As a group, analysts forecast that Xilio Therapeutics will post -1.14 earnings per share for the current fiscal year.

Institutional Trading of Xilio Therapeutics

A hedge fund recently raised its stake in Xilio Therapeutics stock. Squarepoint Ops LLC increased its stake in Xilio Therapeutics, Inc. (NASDAQ:XLO) by 39.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 328,794 shares of the company’s stock after purchasing an additional 93,338 shares during the period. Squarepoint Ops LLC owned 0.63% of Xilio Therapeutics worth $277,000 as of its most recent SEC filing. Institutional investors own 54.29% of the company’s stock.

Xilio Therapeutics Company Profile

Xilio Therapeutics is a clinical?stage biotechnology company focused on the discovery and development of tumor?targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro?drug versions of potent immune?modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin?12 (IL?12) and interleukin?2 (IL?2) molecules fused to tumor?binding antibodies or peptide ligands.